Filing Flows › Rani Therapeutics Holdings (RANI) › R&D spending
Rani Therapeutics Holdings (RANI) R&D spending by quarter
Rani Therapeutics Holdings' R&D spending was $5.0M in Q2 2026 (second quarter 2026), -3% from Q1 2026. Over the last 5 quarters it ranged from $4.9M (Q4 2025) to $6.8M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $5.0M | -3% | — |
| Q1 2026 | $5.2M | +5% | -21% |
| Q4 2025 | $4.9M | -25% | -28% |
| Q1 2025 | $6.6M | -4% | — |
| Q4 2024 | $6.8M | — | — |
Q2 2026 at a glance
Rani Therapeutics Holdings, Q2 2026: revenue $1.7M, operating margin -516.9%, net loss $8.4M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Rani Therapeutics Holdings' R&D spending?
Rani Therapeutics Holdings' R&D spending was $5.0M in Q2 2026 (second quarter 2026), -3% from Q1 2026.
How has Rani Therapeutics Holdings' R&D spending changed?
Over the last 5 quarters it ranged from $4.9M (Q4 2025) to $6.8M (Q4 2024).
Q2 2026 results → · How Rani Therapeutics Holdings makes money →